Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanne Fourie

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summaryPaul G Kluetz, Yang-Min Ning, V Ellen Maher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summaryYangmin M Ning, William Pierce, V Ellen Maher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 MutationSandra J Casak, Shan Pradhan, Lola A Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project RenewalSundeep Agrawal, Clara Lee, William F Pierce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis ReviewAbigail L Koch, Paz J Vellanki, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 24, 2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summaryPaul G Kluetz, Yang-Min Ning, V Ellen Maher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2013
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summaryYangmin M Ning, William Pierce, V Ellen Maher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 MutationSandra J Casak, Shan Pradhan, Lola A Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project RenewalSundeep Agrawal, Clara Lee, William F Pierce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis ReviewAbigail L Koch, Paz J Vellanki, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Pageof 4